XBiotech Inc. (XBIT) shareholders
XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.96+0.00 (0.00%)
Close on Nov 13, 2026Market cap $59.76MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.5%
2M of 30M shares
Institutional holders
36
4 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $854.66K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| John Simard | 5,719,775 | 17.70% | 13G (passive) amendment | Dec 31, 2025 |
| Thomas Gut | 3,914,111 | – | 13G (passive) amendment | Dec 31, 2023 |
| W. Thorpe McKenzie | 3,006,259 | 9.76% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XBIT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 321,146 | 1.05% | $738.64K | +28,042 | 0.00% |
| Geode Capital Management, LLC | 214,116 | 0.70% | $492.76K | −16,904 | 0.00% |
| Vanguard Capital Management LLC | 200,182 | 0.66% | $460.42K | −789 | 0.00% |
| RBF Capital, LLC | 198,501 | 0.65% | $456.55K | – | 0.02% |
| Morgan Stanley | 147,880 | 0.49% | $340.12K | −17,674 | 0.00% |
| Bridgeway Capital Management, LLC | 98,447 | 0.32% | $226.43K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 92,365 | 0.30% | $212.44K | +789 | 0.00% |
| Millennium Management LLC | 79,330 | 0.26% | $182.46K | −26,210 | 0.00% |
| State Street Corp | 73,006 | 0.24% | $167.91K | – | 0.00% |
| Northern Trust Corp | 66,258 | 0.22% | $152.39K | −9,829 | 0.00% |
| Empowered Funds, LLC | 59,547 | 0.20% | $136.96K | – | 0.00% |
| Renaissance Technologies LLC | 41,663 | 0.14% | $95.83K | +19,225 | 0.00% |
| Bank of New York Mellon Corp | 39,355 | 0.13% | $90.52K | – | 0.00% |
| Dimensional Fund Advisors LP | 36,053 | 0.12% | $82.99K | – | 0.00% |
| Squarepoint Ops LLC | 34,757 | 0.11% | $79.94K | −6,457 | 0.00% |
| Qube Research & Technologies Ltd | 33,570 | 0.11% | $77.21K | +14,879 | 0.00% |
| Gsa Capital Partners Llp | 30,654 | 0.10% | $71.00K | New | 0.00% |
| Citadel Advisors LLC | 29,192 | 0.10% | $67.14K | New | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 27,943 | 0.09% | $64.27K | −720 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 26,464 | 0.09% | $60.87K | −700 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 36 | 2M | 6.5% | 4 / 5 | 12 / 3 | 0M | 0M |
| Q1 2026 | 37 | 2M | 6.5% | 6 / 8 | 13 / 8 | 0M | 1M |
| Q4 2025 | 41 | 2M | 8.2% | 4 / 9 | 16 / 8 | 1M | 1M |
| Q3 2025 | 48 | 3M | 9.6% | 4 / 10 | 23 / 9 | 0M | 1M |
| Q2 2025 | 53 | 3M | 11.2% | 16 / 12 | 19 / 18 | 1M | 2M |
| Q1 2025 | 55 | 4M | 14.7% | 9 / 9 | 22 / 6 | 0M | 0M |
| Q4 2024 | 53 | 5M | 15.5% | 10 / 18 | 12 / 7 | 0M | 0M |
| Q3 2024 | 50 | 5M | 15.9% | 10 / 23 | 6 / 5 | 2M | 0M |
| Q2 2024 | 46 | 5M | 14.8% | 13 / 18 | 10 / 12 | 2M | 1M |
| Q1 2024 | 46 | 4M | 14.1% | 10 / 16 | 10 / 3 | 1M | 0M |
| Q4 2023 | 39 | 4M | 11.7% | 5 / 15 | 8 / 3 | 0M | 0M |
| Q3 2023 | 37 | 3M | 11.0% | 3 / 9 | 10 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
14 funds held XBIT in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XBIT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 200,182 | 0.66% | $460.42K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 110,502 | 0.36% | $267.41K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 78,591 | 0.26% | $180.76K | 0.01% | Jun 30, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 59,547 | 0.20% | $136.96K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Fund | 38,900 | 0.13% | $89.47K | 0.09% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 35,154 | 0.12% | $85.07K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 27,507 | 0.09% | $66.57K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 16,960 | 0.06% | $41.04K | 0.00% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 13,228 | 0.04% | $32.01K | 0.00% | May 31, 2026 |
| JNL/DFA U.S. Small Cap Fund | 6,066 | 0.02% | $13.95K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 5,290 | 0.02% | $12.17K | 0.01% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 4,871 | 0.02% | $11.79K | 0.00% | May 31, 2026 |
| AST Small-Cap Equity Portfolio | 2,660 | 0.01% | $6.12K | 0.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value Fund | 282 | 0.00% | $682 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jan-Paul Simard | Co-Chief Executive Officer | – | – | Oct 28, 2026 |
| John Simard | Director, 10% owner | 4,261,690 | 13.98% | Nov 13, 2026 |
| David Spencer Soffer | Director | – | – | Nov 12, 2025 |
| Thomas Martin Kuendig | Director | 300,000 | 0.98% | Nov 12, 2025 |
| Tevi David Troy | Director | – | – | Nov 12, 2025 |
| Craig Evan Rademaker | Director | 170,985 | 0.56% | Nov 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Simard Director, 10% owner | Nov 3, 2026 | Buy | +70,000 | $2.05 | $143.41K | 4,261,690 |
| John Simard Director, 10% owner | Oct 26, 2026 | Buy | +368,524 | $1.93 | $711.25K | 4,191,690 |
| W. Thorpe McKenzie Director, 10% owner | Dec 16, 2021 | Option exercise | +250,000 | $10.00 | $2.50M | 2,810,964 |
| W. Thorpe McKenzie Director, 10% owner | Dec 16, 2021 | Tax withholding | −213,493 | $11.71 | $2.50M | 2,597,471 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 18, 2021 | Sale | −33,000 | $13.07 | $431.31K | 3,823,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 15, 2021 | Sale | −17,000 | $13.32 | $226.44K | 3,856,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 14, 2021 | Sale | −21,125 | $12.90 | $272.51K | 3,873,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 13, 2021 | Sale | −10,875 | $12.83 | $139.53K | 3,962,452 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 12, 2021 | Sale | −18,000 | $12.77 | $229.86K | 3,973,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 7, 2021 | Sale | −39,286 | $12.45 | $489.11K | 3,923,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 6, 2021 | Sale | −10,714 | $12.53 | $134.25K | 3,962,452 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 5, 2021 | Sale | −14,218 | $12.66 | $180.00K | 3,973,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 4, 2021 | Sale | −23,681 | $13.08 | $309.75K | 3,987,384 |
| John Simard Chief Executive Officer, Director, 10% owner | Oct 1, 2021 | Sale | −19,684 | $13.23 | $260.42K | 4,011,065 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 30, 2021 | Sale | −18,558 | $13.07 | $242.55K | 4,030,749 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 29, 2021 | Sale | −16,396 | $13.41 | $219.87K | 4,049,307 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 28, 2021 | Sale | −6,263 | $14.27 | $89.37K | 4,065,703 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 27, 2021 | Sale | −29,890 | $14.81 | $442.67K | 4,071,966 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 24, 2021 | Sale | −11,418 | $14.49 | $165.45K | 4,101,856 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 23, 2021 | Sale | −9,892 | $14.68 | $145.21K | 4,113,274 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 22, 2021 | Sale | −19,669 | $15.14 | $297.79K | 4,123,166 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 21, 2021 | Sale | −16,860 | $15.24 | $256.95K | 4,142,835 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 20, 2021 | Sale | −13,471 | $15.06 | $202.87K | 4,159,695 |
| John Simard Chief Executive Officer, Director, 10% owner | Jul 14, 2021 | Sale | −50,000 | $18.15 | $907.50K | 4,173,166 |
| Peter Libby Director | Jul 9, 2021 | Option exercise | +25,000 | $7.76 | $194.00K | 25,000 |
| Donald H. MacAdam Director | Jul 9, 2021 | Option exercise | +10,000 | $4.40 | $44.00K | 10,000 |
| John Simard Chief Executive Officer, Director, 10% owner | Mar 22, 2021 | Option exercise | +500,000 | $7.50 | $3.75M | 4,223,166 |
| Street Financial S.A. Bay 10% owner | Dec 18, 2020 | Sale | −1,173,033 | $18.78 | $22.03M | 1,981,515 |
| Street Financial S.A. Bay 10% owner | Dec 2, 2020 | Sale | −182,836 | $18.42 | $3.37M | 3,154,548 |
| W. Thorpe McKenzie Director, 10% owner | Nov 19, 2020 | Sale | −375,000 | $18.30 | $6.86M | 2,560,964 |
| John Simard Chief Executive Officer, Director, 10% owner | Sep 18, 2020 | Other | −500,000 | – | – | 3,723,166 |
| Sushma Shivaswamy Chief Scientific Officer | Sep 15, 2020 | Sale | −20,668 | $20.00 | $413.36K | 0 |
| Sushma Shivaswamy Chief Scientific Officer | Sep 15, 2020 | Option exercise | +20,668 | $7.50 | $155.01K | 20,668 |
| Sushma Shivaswamy Chief Scientific Officer | Sep 10, 2020 | Option exercise | +19,332 | $7.50 | $144.99K | 19,332 |
| Sushma Shivaswamy Chief Scientific Officer | Sep 10, 2020 | Sale | −19,332 | $20.01 | $386.83K | 0 |
| Queena Han VP Finance & HR | Sep 1, 2020 | Option exercise | +30,000 | $4.24 | $127.20K | 30,000 |
| Queena Han VP Finance & HR | Sep 1, 2020 | Option exercise | +27,692 | $4.16 | $115.20K | 57,692 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Sale | −5,000 | $19.65 | $98.25K | 0 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Option exercise | +18,700 | $7.50 | $140.25K | 18,700 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Sale | −18,700 | $19.65 | $367.46K | 0 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Option exercise | +12,308 | $4.16 | $51.20K | 12,308 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Sale | −12,500 | $19.65 | $245.62K | 0 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Option exercise | +3,333 | $4.14 | $13.80K | 3,333 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Sale | −3,333 | $19.65 | $65.49K | 0 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Option exercise | +12,500 | $5.26 | $65.75K | 12,500 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Sale | −12,308 | $19.65 | $241.85K | 0 |
| Queena Han VP Finance & HR | Aug 24, 2020 | Option exercise | +5,000 | $15.00 | $75.00K | 5,000 |
| Queena Han VP Finance & HR | Aug 17, 2020 | Sale | −1,300 | $19.30 | $25.09K | 0 |
| Queena Han VP Finance & HR | Aug 17, 2020 | Option exercise | +1,300 | $7.50 | $9.75K | 1,300 |
| Street Financial S.A. Bay 10% owner | Feb 19, 2020 | Sale | −1,662,616 | $6.38 | $10.61M | 3,337,384 |
| John Simard Chief Executive Officer, Director, 10% owner | Feb 12, 2020 | Returned to company | −2,103,894 | $30.00 | $63.12M | 4,223,166 |
| W. Thorpe McKenzie Director, 10% owner | Feb 12, 2020 | Returned to company | −15,874 | $30.00 | $476.22K | 31,864 |
| W. Thorpe McKenzie Director, 10% owner | Feb 12, 2020 | Returned to company | −33,252 | $30.00 | $997.56K | 66,748 |
| W. Thorpe McKenzie Director, 10% owner | Feb 12, 2020 | Returned to company | −3,825 | $30.00 | $114.75K | 7,676 |
| W. Thorpe McKenzie Director, 10% owner | Feb 12, 2020 | Returned to company | −1,462,636 | $30.00 | $43.88M | 2,935,964 |
| Jan-Paul Waldin Director | Feb 12, 2020 | Returned to company | −99,757 | $30.00 | $2.99M | 200,243 |
| Thomas Gut 10% owner | Feb 12, 2020 | Returned to company | −1,949,929 | $30.00 | $58.50M | 3,914,111 |
| Thomas Gut 10% owner | Feb 12, 2020 | Returned to company | −1,947,584 | $30.00 | $58.43M | 3,916,456 |
| Thomas Gut 10% owner | Feb 12, 2020 | Returned to company | −1,868,870 | $30.00 | $56.07M | 3,995,170 |
| W. Thorpe McKenzie Director, 10% owner | Feb 12, 2020 | Returned to company | −15,214 | $30.00 | $456.42K | 32,524 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.30%
0M shares short
Days to cover
2.6
At 0M shares a day
Change since last report
+4.8%
From 0M shares
Short volume, 20 days
47.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of XBiotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,308 shares on Oct 1, 2026 over the last 90 days.
See a number that looks wrong?